MedPath

Contribution of a High-resolution Diffusion Sequence at 3T for the Detection of Acute Punctate Ischemic Brain Lesions

Not yet recruiting
Conditions
Stroke
Registration Number
NCT05232500
Lead Sponsor
Fondation Hôpital Saint-Joseph
Brief Summary

Stroke is a public health issue and a priority for our institution. MRI plays an essential role in the management of stroke, its contribution being diagnostic, etiological and prognostic.

Among the MRI sequences used in stroke emergencies, the diffusion sequence plays a key role in highlighting ischemic lesions as early as the hyperacute phase, even though the other sequences in the protocol do not reveal any anomaly. This sequence alone conditions the management of patients, particularly in the context of "thrombolysis emergencies".

It has been shown that the sensitivity of the diffusion sequence for the detection of ischemic lesions can directly depend on acquisition parameters such as b value, slice thickness or spatial resolution.

Recent advances in MRI now allow us to perform diffusion sequences with higher spatial resolution. The matrix is an important acquisition parameter of MRI sequences defining the ability of the sequence to distinguish 2 pixels in the acquisition plane. The higher the matrix, the higher the spatial resolution of the sequence in the acquisition plane.

At the Saint-Joseph Hospital, we have a new 3T MRI since September 2020 allowing the acquisition in clinical routine of a more resolved diffusion sequence: 160x200 matrix ("high resolution" diffusion, HR), against 128x140 ("standard" diffusion usually). These two sequences are acquired in particularly short acquisition times (1 minute 37 seconds). This HR diffusion sequence is performed as part of routine care since September 2020 for specific situations: absence of lesion highlighted on the standard diffusion sequence while the patient has a suggestive symptomatology (especially for lesions of the brainstem), search for lesion in other vascular territories (thus in favor of an embolic origin) in a patient who presents an isolated ischemic lesion or ischemic lesions in a single territory.

It has been reported in the literature that increasing the spatial resolution can reveal small lesions that were not visible on more conventional sequences. There is a clear rationale for seeking to improve the detection of small lesions (\<5 mm) because their detection may have important therapeutic implications for many patients (particularly in the context of thrombolysis emergencies, transient ischemic attacks, or amnesic strokes).

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients with age ≥ 18 years
  • Patients who underwent a 3T brain MRI for suspected stroke/TIA (MRI performed within 7 days of clinical symptomatology) and for whom the "HR" diffusion sequence was considered useful for diagnosis
  • French-speaking patient
Exclusion Criteria
  • Patient under guardianship or curatorship
  • Patient deprived of liberty
  • Patient under court protection
  • Patient objecting to the use of his data for this research

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sensitivity of "standard" and "high resolution" diffusion sequencesDay 1

This outcome corresponds to the comparison of the number of small (\< 5 mm) acute ischemic lesions visible on standard and high resolution diffusion sequences.

Secondary Outcome Measures
NameTimeMethod
Image quality (CNR) is maintained with this new HR sequence compared to the classic sequenceDay 1

This outcome corresponds to the comparison of image quality between conventional and high-resolution diffusion sequences by measuring the contrast-to-noise ratio (CNR) of ischemic lesions.

Image quality (SNR) is maintained with this new HR sequence compared to the classic sequenceDay 1

This outcome corresponds to the comparison of image quality between conventional and high-resolution diffusion sequences by measuring the signal-to-noise ratio (SNR) of ischemic lesions.

Trial Locations

Locations (1)

Groupe Hospitalier Paris Saint-Joseph

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath